New cannabis-based treatment shows promise for late-stage dementia agitation

For years, the race to stop Alzheimer's disease has centered on catching it early—on the people who might still be saved from its worst effects. But that focus has left a gap, one that matters urgently to millions of Americans already deep in the disease and the families keeping them alive. What happens when prevention is no longer possible? How do you make a life worth living when the mind is nearly gone?

Researchers at the University of Kentucky's Sanders-Brown Center on Aging have begun answering that question on two fronts. The first involves a specific compound. The second involves meeting families where they actually are.

In July, at the Alzheimer's Association International Conference in London, Sanders-Brown presented results from the LiBBY trial, a twelve-week study of 120 people with advanced dementia. Half received a treatment combining THC and CBD—the two main compounds in cannabis. Half received placebo. The difference was striking. By week twelve, 87.2 percent of those on the active treatment showed clinician-rated improvement in agitation, compared with 23.6 percent on placebo. The benefits appeared within two weeks and held steady through the end of the study. The reduction in agitation scores averaged eight points—a magnitude that Greg Jicha, the director of clinical trials at Sanders-Brown, called "quite striking." Equally important, the patients were not simply sedated into compliance. They remained awake and alert, just more comfortable and less agitated. Caregivers reported significant improvements in their own quality of life as well. Researchers monitored for side effects carefully and found that serious adverse events occurred at similar rates in both groups, with none linked to the study medication itself.

Jicha was careful to note that this does not mean any cannabis product off a shelf will work the same way. The trial tested a specific formulation at specific doses. But the findings open a door. They suggest that a carefully designed cannabis-derived treatment might become part of how doctors manage the behavioral storms that often accompany late-stage dementia—storms that can exhaust caregivers and diminish whatever quality of life remains.

The second part of Sanders-Brown's answer is more immediate. The center has launched CARE Compass, a free online resource built specifically for families managing advanced dementia. It is organized around four categories: Care Needs, Activities, Resources, and Education. Under Care Needs, families find videos and practical guidance on bathing, dressing, positioning, feeding, and how caregivers can find rest. Activities offers ideas for maintaining connection through music, movement, and calming techniques. Resources provides checklists and links to national organizations. Education features specialists discussing agitation, medical concerns, and how to recognize pain or distress in someone who can no longer speak it aloud.

The program reflects something the LiBBY trial itself demonstrated: that people with very advanced dementia can participate in research when researchers come to them. Many participants in the study lived at home and had mobility limitations that made travel difficult. So Sanders-Brown sent teams across Kentucky, sometimes driving two hours each way to meet families in their living rooms. That required researchers to think not just about the patient but about the exhausted person providing daily care—to understand both sets of needs if the work was going to succeed.

That same philosophy shapes CARE Compass. The disease does not follow a single path. It progresses differently for every person, and the challenges shift over time. The resource is designed to be something families return to as those needs change, a tool that meets them where they are in the journey.

For Jicha and his team, the LiBBY results and CARE Compass together represent a commitment to the people left behind by the field's focus on prevention. "We've not forsaken their loved ones in the later stages of disease," he said, "nor have we forsaken the family members and caregivers that take on this tremendous task of love and commitment." The work ahead will likely involve testing whether similar cannabis-derived approaches might help at earlier stages of dementia or in other populations. But for now, these two tools—a potential new medication and a practical guide for living—offer something concrete to families who have watched prevention slip away and are simply trying to make the days ahead bearable.